NEW YORK, Feb. 20, 2015 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) today announced that it is participating in the 2015 RBC Capital Markets Healthcare Conference at the New York Palace Hotel in New York City. Assembly's Chief Executive Officer Derek Small and Chief Medical Officer Uri Lopatin will present on February 25, 2015 at 4:05pm ET. A breakout session will follow.
The Assembly presentation will be webcast live at: http://www.veracast.com/webcasts/rbc/healthcare2015/15215363045.cfm. The archived webcast will be available starting approximately one hour after the live event and will remain archived at this address for 90 days.
About Assembly Biosciences
Assembly Biosciences, Inc. is a public biopharmaceutical company developing novel oral therapies for the cure of intractable infectious diseases, focusing on hepatitis B virus (HBV) and C. difficile-associated infections (CDAD). Its HBV-Cure research team is discovering and developing multiple core protein allosteric modifiers (CpAMs) with the potential to modulate the HBV core protein—a polyfunctional essential viral protein-—at multiple complementary points in the viral lifecycle. The goal is to eradicate the infection with an orally-administered regimen. Assembly is uniquely positioned to execute on this strategy, with a senior scientific team that has over 30 years of combined experience working on HBV. The company's CDAD program is based on the targeted delivery of novel microbiome-based therapies in a proprietary oral formulation. Assembly has created a network of world-class microbiome scientists from academia and industry to help advance this innovative program. For more information visit www.assemblybio.com.
CONTACT: Corporate:
Assembly Biosciences, Inc.
David Barrett
646-706-5208
dbarrett@assemblybio.com
Media:
BLL Partners LLC
Barbara Lindheim
212-584-2276
blindheim@bllbiopartners.com
